CANDIN is the only Candida albicans extract-based skin testing antigen for intradermal injection licensed by the FDA to assess cell-mediated hypersensitivity to Candida albicans.
CANDIN should not be used to diagnose or treat Type 1 allergy to Candida albicans.
Every lot of CANDIN is tested in a clinical trial for consistency of potency.
CANDIN has demonstrated consistent clinical potency over its history.
(Data on File)
CANDIN may be useful in evaluating patients suspected of having a reduced cellular immune response in patients that respond to candida antigen.
Because some persons with normal cellular immunity are not hypersensitive to Candida (see below), concurrent use of other cell-mediated hypersensitivity skin testing antigens is recommended.
(Normals include pooled data from CANDIN-treated subjects in trials supporting CANDIN and SPHERUSOL.)
CANDIN is cited as a control for tuberculin skin testing (TST) to rule out anergy as a possible factor in persons who are skin-test negative to tuberculin.
Ann Pharmacother. 2004 Jun;38(6):973-7. Epub 2004 Apr 14.
J Rheumatol. 2008 May;35(5):770-5.
The following third-party website was provided for your convenience, and Nielsen BioSciences, Inc. does not endorse, verify, or otherwise support the information contained in these websites. You are subject to the legal terms and conditions of use for third-party websites.